A previously overlooked dopamine-producing brain circuit drives hedonic eating, or eating for pleasure, according to a new ...

Several studies have been done on the myriad list of side effects that come from popular weight loss drugs.  A new study ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.

CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

In the past year, treatments such as Wegovy, Mounjaro and Zepbound have become household names. But there are many questions ...

The Company has entered into a securities purchase agreement with an entity beneficially owned by Gregg Williams, the Chairman of the Company’s board of directors. The private placement was priced “at ...